We are proud of our argonauts’ dedication to delivering innovative treatments to patients in need. Our recent FDA approval in chronic inflammatory demyelinating polyneuropathy (CIDP) is a testament to the value of collaborations with disease biology experts and the autoimmune patient community. Discover more about our work to advance #CIDP treatment: https://bit.ly/4cFeVZb #TogetherWeDiscover
This is good news for a part of the CIDP community patients waiting for a long time innovative treatment. Let’s work together now to enlarge the access to European CIDP patients. EPODIN . #CIDP #patientneeds #innovativetreatment
Congratulations on the FDA approval for CIDP treatment! Your collaboration with experts and patients underscores a commitment to innovative healthcare solutions.
Amazing! 👏🏻
Managing Partner VVGB Advocaten- Chairman of the Board of Directors at argenx SE
1moWe are truly proud of the entire Argonaut team and unique argenx culture that enables us to be ambitious and reach our goals for all these patients with unmet or unsufficiently met medical needs - 👍👍👍